Get the Stockscreener App
15.25
0.07%
-0.010
After Hours:
15.23
-0.02
-0.13%
Hutchmed China Limited Adr stock is traded at $15.25, with a volume of 68,602.
It is down -0.07% in the last 24 hours and down -8.30% over the past month.
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
See More
Previous Close:
$15.26
Open:
$15.38
24h Volume:
68,602
Relative Volume:
0.84
Market Cap:
$2.60B
Revenue:
$420.26M
Net Income/Loss:
$-41.97M
P/E Ratio:
-61.00
EPS:
-0.25
Net Cash Flow:
$-65.34M
1W Performance:
+1.73%
1M Performance:
-8.30%
6M Performance:
-19.91%
1Y Performance:
-9.23%
1-Day Range:
$15.09
$15.57
1-Week Range:
$14.00
$15.57
52-Week Range:
$12.84
$21.92
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
15.25 | 2.60B | 420.26M | -41.97M | -65.34M | -0.25 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - Yahoo Finance
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
Blue Trust Inc. Purchases 3,057 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance UK
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Vanguard Personalized Indexing Management LLC Buys 1,168 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Rhumbline Advisers Boosts Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Research Analysts Set Expectations for HUTCHMED (China) Limited’s FY2025 Earnings (NASDAQ:HCM) - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200 Day Moving Average of $284.47 - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Yahoo Finance
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
CN National Reimbursement Drug List Raises Requirements on Innovative Drugs: Report - AASTOCKS.com
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance
International companies to host live webcasts at Deutsche - GlobeNewswire
7 Best-Performing China Stocks for October 2024 - NerdWallet
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com
Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma - OncLive
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
CMBI Raises HUTCHMED (00013.HK) TP to $35.61; Fruquintinib's Overseas Sales Beat - AASTOCKS.com
HSI Closes Down 39 pts; CN Property & Car Stocks Wane; POWER ASSETS Rises 5% Against Mkt - AASTOCKS.com
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):